Acetylon Pharmaceuticals Presents Preclinical Data for Selective HDAC1/2 Inhibitors For The Treatment Of Sickle Cell Disease And ß-Thalassemia At The American Society of Hematology Annual Meeting

Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, announced that positive preclinical data for its selective HDAC1/2 inhibitors for the treatment of sickle cell disease (SCD) and ß-thalassemia (bT) were presented at the 55th Annual Meeting of the American Society of Hematology (ASH) in New Orleans, LA.

Help employers find you! Check out all the jobs and post your resume.